Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Cannabinoid Receptor 1 Antibodies

Close filters
No results were found for the filter!
Citations
NEW
Immunohistochemical Identification of Agonist-induced Serine425 phosphorylation of the Cannabinoid Receptor 1 in mouse brain
pS425-CB1 (IHC-grade phospho-Cannabinoid...
Serine425 (S425) is major phosphorylation site of the Cannabinoid Receptor 1 (CB1). The pS425-CB1 antibody detects phosphorylation in response to agonists. S425 phosphorylation is likely to be involved in efficient ligand sequestration...
$ 500.00 *
Details

Nervous system responses to Δ9-THC and other cannabinoid receptor agonists include therapeutically beneficial effects of analgesia, attenuation of the nausea and vomiting in cancer chemotherapy, appetite stimulation in wasting syndromes, and decreased intestinal motility. Untoward side effects accompanying these therapeutic responses include alterations in cognition and memory, dysphoria/euphoria and sedation. Most CB1 receptors are located at central or peripheral nerve terminals and their main function is to mediate inhibition of on-going release of certain excitatory and inhibitory neurotransmitters. CB1 cannabinoid receptors are coupled to pertussis toxin-sensitive Gi/Go proteins in a manner that leads to the inhibition of adenylate cyclase activity, regulation of Ca2+ channels inwardly rectifying K+ channels. CB1 receptors are regulated by phosphorylation of carboxyl-terminal serine425 (pS425-CB1), serine429 (pS429-CB1) and serine441 (pS441-CB1). This nomenclature refers to the human CB1 receptor. This phosphorylation motif is conserved across species but corresponds to pS426-CB1 and pS430-CB1 in mice and rats. For more information on CB1 pharmacology please refer to the IUPHAR database. For further reading refer to:

Fritzwanker S, Nagel F, Kliewer A, Schulz S. In situ Visualization of opioid and cannabinoid drug effects using phosphosite-specific GPCR antibodies. bioRxiv 2022.06.14.496067; doi: https://doi.org/10.1101/2022.06.14.496067

Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev. 2010 Dec;62(4):588-631. doi: 10.1124/pr.110.003004. PMID: 21079038; PMCID: PMC2993256.

Nervous system responses to Δ9-THC and other cannabinoid receptor agonists include therapeutically beneficial effects of analgesia, attenuation of the nausea and vomiting in cancer... read more »
Close window
Cannabinoid Receptor 1 Antibodies

Nervous system responses to Δ9-THC and other cannabinoid receptor agonists include therapeutically beneficial effects of analgesia, attenuation of the nausea and vomiting in cancer chemotherapy, appetite stimulation in wasting syndromes, and decreased intestinal motility. Untoward side effects accompanying these therapeutic responses include alterations in cognition and memory, dysphoria/euphoria and sedation. Most CB1 receptors are located at central or peripheral nerve terminals and their main function is to mediate inhibition of on-going release of certain excitatory and inhibitory neurotransmitters. CB1 cannabinoid receptors are coupled to pertussis toxin-sensitive Gi/Go proteins in a manner that leads to the inhibition of adenylate cyclase activity, regulation of Ca2+ channels inwardly rectifying K+ channels. CB1 receptors are regulated by phosphorylation of carboxyl-terminal serine425 (pS425-CB1), serine429 (pS429-CB1) and serine441 (pS441-CB1). This nomenclature refers to the human CB1 receptor. This phosphorylation motif is conserved across species but corresponds to pS426-CB1 and pS430-CB1 in mice and rats. For more information on CB1 pharmacology please refer to the IUPHAR database. For further reading refer to:

Fritzwanker S, Nagel F, Kliewer A, Schulz S. In situ Visualization of opioid and cannabinoid drug effects using phosphosite-specific GPCR antibodies. bioRxiv 2022.06.14.496067; doi: https://doi.org/10.1101/2022.06.14.496067

Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev. 2010 Dec;62(4):588-631. doi: 10.1124/pr.110.003004. PMID: 21079038; PMCID: PMC2993256.

Recently viewed